{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T05:19:27Z","timestamp":1787894367898,"version":"build-2784847793"},"reference-count":144,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gyn\u00e9cologie Obst\u00e9trique Fertilit\u00e9 & S\u00e9nologie\u00a0"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.gofs.2021.03.015","type":"journal-article","created":{"date-parts":[[2021,3,20]],"date-time":"2021-03-20T06:16:10Z","timestamp":1616220970000},"page":"420-437","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["M\u00e9nopause, traitement hormonal de m\u00e9nopause et ost\u00e9oporose. RPC Les femmes m\u00e9nopaus\u00e9es du CNGOF et du GEMVi"],"prefix":"10.1016","volume":"49","author":[{"given":"J.-M.","family":"Pouill\u00e8s","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Gosset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Tr\u00e9mollieres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gofs.2021.03.015_bib0725","series-title":"Livre blanc des \u00e9tats g\u00e9n\u00e9raux de l\u2019ost\u00e9oporose","author":"Grange","year":"2016"},{"key":"10.1016\/j.gofs.2021.03.015_bib0730","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.tem.2012.03.008","article-title":"Estrogen and the skeleton","volume":"23","author":"Khosla","year":"2012","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.gofs.2021.03.015_bib0735","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1210\/jc.2007-1876","article-title":"Bone mineral density changes during the menopause transition in a multiethnic cohort of women","volume":"93","author":"Finkelstein","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.gofs.2021.03.015_bib0740","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/jbmr.534","article-title":"Bone mineral density loss in relation to the final menstrual period in a multiethnic cohort: results from the Study of Women's Health Across the Nation (SWAN)","volume":"27","author":"Greendale","year":"2012","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.gofs.2021.03.015_bib0745","doi-asserted-by":"crossref","first-page":"E654","DOI":"10.1210\/jc.2012-3651","article-title":"Serum sex steroid levels and longitudinal changes in bone density in relation to the final menstrual period","volume":"98","author":"Crandall","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.gofs.2021.03.015_bib0750","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1210\/jc.2012-4113","article-title":"Changes in bone resorption across the menopause transition: effects of reproductive hormones, body size, and ethnicity","volume":"98","author":"Sowers","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.gofs.2021.03.015_bib0755","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1002\/jbmr.2889","article-title":"Urinary N-telopeptide and rate of bone loss over the menopause transition and early postmenopause","volume":"31","author":"Shieh","year":"2016","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.gofs.2021.03.015_bib0760","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1359\/jbmr.040916","article-title":"Population-based study of age and sex differences in bone volumetric density, size, geometry, and structure at different skeletal sites","volume":"19","author":"Riggs","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.gofs.2021.03.015_bib0765","doi-asserted-by":"crossref","first-page":"e10116","DOI":"10.1002\/jbm4.10116","article-title":"Urinary N-Telopeptide as predictor of onset of menopause-related bone loss in pre- and perimenopausal women","volume":"3","author":"Shieh","year":"2019","journal-title":"JBMR Plus"},{"key":"10.1016\/j.gofs.2021.03.015_bib0770","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.bone.2007.03.019","article-title":"Transmenopausal changes in the trabecular bone structure","volume":"41","author":"Akhter","year":"2007","journal-title":"Bone"},{"key":"10.1016\/j.gofs.2021.03.015_bib0775","doi-asserted-by":"crossref","first-page":"e1872","DOI":"10.1210\/clinem\/dgz056","article-title":"Trabecular bone score declines during the menopause transition: the Study of Women's Health Across the Nation (SWAN)","volume":"105","author":"Greendale","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.gofs.2021.03.015_bib0780","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1359\/jbmr.070815","article-title":"Trabecular structure quantified with the MRI-based virtual bone biopsy in postmenopausal women contributes to vertebral deformity burden independent of areal vertebral BMD","volume":"23","author":"Ladinsky","year":"2008","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.gofs.2021.03.015_bib0785","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1172\/JCI112462","article-title":"Rates of bone loss in the appendicular and axial skeletons of women. Evidence of substantial vertebral bone loss before menopause","volume":"77","author":"Riggs","year":"1986","journal-title":"J Clin Invest"},{"key":"10.1016\/j.gofs.2021.03.015_bib0790","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/jbmr.5650090304","article-title":"Influence of early age at menopause on vertebral bone mass","volume":"9","author":"Pouill\u00e8s","year":"1994","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.gofs.2021.03.015_bib0795","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1097\/gme.0b013e31804c793d","article-title":"Effect of early menopause on bone mineral density and fractures","volume":"14","author":"Gallagher","year":"2007","journal-title":"Menopause"},{"key":"10.1016\/j.gofs.2021.03.015_bib0800","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/GME.0000000000000775","article-title":"Age of menopause and fracture risk in postmenopausal women randomized to calcium + vitamin D, hormone therapy, or the combination: results from the Women's Health Initiative Clinical Trials","volume":"24","author":"Sullivan","year":"2017","journal-title":"Menopause"},{"key":"10.1016\/j.gofs.2021.03.015_bib0805","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.jocd.2019.07.007","article-title":"The impact of smoking on bone metabolism, bone mineral density and vertebral fractures in postmenopausal women","volume":"23","author":"Trevisan","year":"2020","journal-title":"J Clin Densitom"},{"key":"10.1016\/j.gofs.2021.03.015_bib0810","first-page":"683","article-title":"Vertebral postmenopausal bone loss is reduced in overweight women: a longitudinal study in 155 early postmenopausal women","volume":"77","author":"Tremollieres","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.gofs.2021.03.015_bib0815","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1002\/jbmr.2303","article-title":"Pleiotropic effects of obesity on fracture risk: the Study of Women's Health Across the Nation","volume":"29","author":"Ishii","year":"2014","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.gofs.2021.03.015_bib0820","first-page":"2263","article-title":"Polymorphism of the aromatase gene in postmenopausal Italian women: distribution and correlation with bone mass and fracture risk","volume":"86","author":"Masi","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.gofs.2021.03.015_bib0825","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1210\/jc.2003-030164","article-title":"Polymorphisms in the P450 c17 (17-hydroxylase\/17,20-Lyase) and P450 c19 (aromatase) genes: association with serum sex steroid concentrations and bone mineral density in postmenopausal women","volume":"89","author":"Somner","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.gofs.2021.03.015_bib0830","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1016\/j.amjmed.2006.07.011","article-title":"The association of bone mineral density with estrogen receptor gene polymorphisms","volume":"119","author":"Greendale","year":"2006","journal-title":"Am J Med"},{"key":"10.1016\/j.gofs.2021.03.015_bib0835","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.maturitas.2005.07.007","article-title":"Estrogen receptor alpha gene polymorphisms are associated with changes in bone remodeling markers and treatment response to estrogen","volume":"53","author":"Rapuri","year":"2006","journal-title":"Maturitas"},{"key":"10.1016\/j.gofs.2021.03.015_bib0840","unstructured":"Haute Autorit\u00e9 de sant\u00e9 (HAS). Les m\u00e9dicaments de l\u2019ost\u00e9oporose. Mise au point 2019. [Disponible sur\u00a0: has-sante.fr\/jcms\/c_1751307\/fr\/les-medicaments-de-l-osteoporose#:\u223c:text=L\u2019alendronate%20Fosamax%C2\u00a0%AE%20et,%C3\u00a0%A9lev%C3\u00a0%A9\u00a0%20de%20fracture%20et%20sont]."},{"key":"10.1016\/j.gofs.2021.03.015_bib0845","doi-asserted-by":"crossref","first-page":"751","DOI":"10.7326\/0003-4819-155-11-201112060-00007","article-title":"Cost-effectiveness of different screening strategies for osteoporosis in postmenopausal women","volume":"155","author":"Nayak","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.gofs.2021.03.015_bib0850","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s11914-011-0060-5","article-title":"A review of osteoporosis diagnosis and treatment options in new and recently updated guidelines on case finding around the world","volume":"9","author":"Leslie","year":"2011","journal-title":"Curr Osteoporos Rep"},{"key":"10.1016\/j.gofs.2021.03.015_bib0855","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.jbspin.2018.02.009","article-title":"2018 update of French recommendations on the management of postmenopausal osteoporosis","volume":"85","author":"Briot","year":"2018","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.gofs.2021.03.015_bib0860","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1001\/jama.2018.6537","article-title":"Screening to prevent osteoporotic fractures: updated evidence report and systematic review for the US Preventive Services Task Force","volume":"319","author":"Viswanathan","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.gofs.2021.03.015_bib0865","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1136\/annrheumdis-2015-207907","article-title":"The accuracy of osteoporotic fracture risk prediction tools: a systematic review and meta-analysis","volume":"74","author":"Marques","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.gofs.2021.03.015_bib0870","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s00198-019-04919-6","article-title":"Performance of predictive tools to identify individuals at risk of non-traumatic fracture: a systematic review, meta-analysis, and meta-regression","volume":"30","author":"Beaudoin","year":"2019","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.gofs.2021.03.015_bib0875","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00198-018-4704-5","article-title":"European guidance for the diagnosis and management of osteoporosis in postmenopausal women","volume":"30","author":"Kanis","year":"2019","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.gofs.2021.03.015_bib0880","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00198-004-1780-5","article-title":"Assessment of fracture risk","volume":"16","author":"Kanis","year":"2005","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.gofs.2021.03.015_bib0885","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1359\/jbmr.070713","article-title":"Clinical risk factors for fractures in multi-ethnic women: the Women's Health Initiative","volume":"22","author":"Cauley","year":"2007","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.gofs.2021.03.015_bib0890","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s00198-007-0380-6","article-title":"An approach for identifying postmenopausal women age 50\u201364 years at increased short-term risk for osteoporotic fracture","volume":"18","author":"Chen","year":"2007","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.gofs.2021.03.015_bib0895","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00198-008-0643-x","article-title":"Risk factors for low bone mass in healthy 40\u201360 year old women: a systematic review of the literature","volume":"20","author":"Waugh","year":"2009","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.gofs.2021.03.015_bib0900","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.bone.2004.03.024","article-title":"A meta-analysis of previous fracture and subsequent fracture risk","volume":"35","author":"Kanis","year":"2004","journal-title":"Bone"},{"key":"10.1016\/j.gofs.2021.03.015_bib0905","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/jbmr.2017","article-title":"A meta-analysis of the association of fracture risk and body mass index in women","volume":"29","author":"Johansson","year":"2014","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.gofs.2021.03.015_bib0910","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00198-004-1640-3","article-title":"Smoking and fracture risk: a meta-analysis","volume":"16","author":"Kanis","year":"2005","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.gofs.2021.03.015_bib0915","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.bone.2004.06.017","article-title":"A family history of fracture and fracture risk: a meta-analysis","volume":"35","author":"Kanis","year":"2004","journal-title":"Bone"},{"key":"10.1016\/j.gofs.2021.03.015_bib0920","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1210\/jc.2014-2601","article-title":"How to predict fragility fracture beyond 10 years? The OFELY study","volume":"99","author":"Sornay-Rendu","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.gofs.2021.03.015_bib0925","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.bone.2007.11.001","article-title":"A reference standard for the description of osteoporosis","volume":"42","author":"Kanis","year":"2008","journal-title":"Bone"},{"key":"10.1016\/j.gofs.2021.03.015_bib0930","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ijcard.2011.10.114","article-title":"Bone mineral density and all-cause, cardiovascular and stroke mortality: a meta-analysis of prospective cohort studies","volume":"166","author":"Qu","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.gofs.2021.03.015_bib0935","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.2147\/CMAR.S188251","article-title":"Relationship between bone mineral density and the risk of breast cancer: a systematic review and dose-response meta-analysis of ten cohort studies","volume":"11","author":"Chen","year":"2019","journal-title":"Cancer Manag Res"},{"issue":"Suppl. 6","key":"10.1016\/j.gofs.2021.03.015_bib0940","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1007\/s001980070002","article-title":"The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation","volume":"11","author":"Delmas","year":"2000","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.gofs.2021.03.015_bib0945","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S8756-3282(00)00248-9","article-title":"Serum CrossLaps for monitoring the response in individuals undergoing antiresorptive therapy","volume":"26","author":"Christgau","year":"2000","journal-title":"Bone"},{"key":"10.1016\/j.gofs.2021.03.015_bib0950","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S2213-8587(17)30184-5","article-title":"Use of bone turnover markers in postmenopausal osteoporosis","volume":"5","author":"Eastell","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.gofs.2021.03.015_bib0955","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13018-019-1100-6","article-title":"Reference markers of bone turnover for prediction of fracture: a meta-analysis","volume":"14","author":"Tian","year":"2019","journal-title":"J Orthop Surg Res"},{"key":"10.1016\/j.gofs.2021.03.015_bib0960","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1359\/jbmr.2000.15.8.1526","article-title":"Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study","volume":"15","author":"Garnero","year":"2000","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.gofs.2021.03.015_bib0965","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1097\/gme.0b013e31825ae17e","article-title":"Bone resorption and fracture across the menopausal transition: the Study of Women's Health Across the Nation","volume":"19","author":"Cauley","year":"2012","journal-title":"Menopause"},{"key":"10.1016\/j.gofs.2021.03.015_bib0970","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgz281","article-title":"The association between fast increase in bone turnover during the menopause transition and subsequent fracture","volume":"105","author":"Shieh","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.gofs.2021.03.015_bib0975","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1210\/jc.2006-1415","article-title":"Effectiveness of bone density measurement for predicting osteoporotic fractures in clinical practice","volume":"92","author":"Leslie","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.gofs.2021.03.015_bib0980","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1359\/JBMR.050304","article-title":"Predictive value of BMD for hip and other fractures","volume":"20","author":"Johnell","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.gofs.2021.03.015_bib0985","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00198-007-0343-y","article-title":"The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women","volume":"18","author":"Kanis","year":"2007","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.gofs.2021.03.015_bib0990","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/jbmr.5650100218","article-title":"Prediction of fracture risk using axial bone mineral density in a perimenopausal population: a prospective study","volume":"10","author":"Kr\u00f6ger","year":"1995","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.gofs.2021.03.015_bib0995","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1359\/JBMR.051205","article-title":"Long-term fracture prediction by DXA and QUS: a 10-year prospective study","volume":"21","author":"Stewart","year":"2006","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.gofs.2021.03.015_bib1000","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1359\/jbmr.020604","article-title":"Ten-year absolute risk of osteoporotic fractures according to BMD T score at menopause: the Danish Osteoporosis Prevention Study","volume":"21","author":"Abrahamsen","year":"2006","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.gofs.2021.03.015_bib1005","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1002\/jbmr.106","article-title":"The FRAX tool in French women: how well does it describe the real incidence of fracture in the OFELY cohort?","volume":"25","author":"Sornay-Rendu","year":"2010","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.gofs.2021.03.015_bib1010","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1002\/jbmr.12","article-title":"Fracture risk prediction using BMD and clinical risk factors in early postmenopausal women: sensitivity of the WHO FRAX tool","volume":"25","author":"Tr\u00e9mollieres","year":"2010","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.gofs.2021.03.015_bib1015","doi-asserted-by":"crossref","first-page":"115543","DOI":"10.1016\/j.bone.2020.115543","article-title":"Premenopausal and early postmenopausal trabecular bone score (TBS) and fracture risk: study of Women's Health Across the Nation (SWAN)","volume":"140","author":"Greendale","year":"2020","journal-title":"Bone"},{"key":"10.1016\/j.gofs.2021.03.015_bib1020","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00198-007-0543-5","article-title":"FRAX and the assessment of fracture probability in men and women from the UK","volume":"19","author":"Kanis","year":"2008","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.gofs.2021.03.015_bib1025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00198-013-2409-3","article-title":"Comparison between various fracture risk assessment tools","volume":"25","author":"Leslie","year":"2014","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.gofs.2021.03.015_bib1030","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s11606-018-4696-z","article-title":"Predicting fracture risk in younger postmenopausal women: comparison of the Garvan and FRAX Risk Calculators in the Women's Health Initiative Study","volume":"34","author":"Crandall","year":"2019","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.gofs.2021.03.015_bib1035","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.jocd.2013.01.004","article-title":"Selection of women aged 50\u201364 yr for bone density measurement","volume":"16","author":"Leslie","year":"2013","journal-title":"J Clin Densitom"},{"key":"10.1016\/j.gofs.2021.03.015_bib1040","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1007\/s00198-015-3025-1","article-title":"Systematic review and meta-analysis of the performance of clinical risk assessment instruments for screening for osteoporosis or low bone density","volume":"26","author":"Nayak","year":"2015","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.gofs.2021.03.015_bib1045","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1002\/jbmr.3717","article-title":"Performance of FRAX and FRAX-based treatment thresholds in women aged 40 years and older: the Manitoba BMD Registry","volume":"34","author":"Crandall","year":"2019","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.gofs.2021.03.015_bib1050","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/jbmr.3636","article-title":"A comparison of US and Canadian osteoporosis screening and treatment strategies in postmenopausal women","volume":"34","author":"Crandall","year":"2019","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.gofs.2021.03.015_bib1055","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s00198-009-1007-x","article-title":"Population screening for osteoporosis risk: a randomised control trial of medication use and fracture risk","volume":"21","author":"Barr","year":"2010","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.gofs.2021.03.015_bib1060","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s00198-019-05226-w","article-title":"Fracture prevention by screening for high fracture risk: a systematic review and meta-analysis","volume":"31","author":"Merlijn","year":"2020","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.gofs.2021.03.015_bib1065","doi-asserted-by":"crossref","first-page":"E249","DOI":"10.1210\/jc.2012-3406","article-title":"Effects of estrogen with micronized progesterone on cortical and trabecular bone mass and microstructure in recently postmenopausal women","volume":"98","author":"Farr","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.gofs.2021.03.015_bib1070","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S8756-3282(00)00272-6","article-title":"Early response in biochemical markers predicts long-term response in bone mass during hormone replacement therapy in early postmenopausal women","volume":"26","author":"Bjarnason","year":"2000","journal-title":"Bone"},{"key":"10.1016\/j.gofs.2021.03.015_bib1075","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1210\/er.2001-5002","article-title":"Meta-analyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women","volume":"23","author":"Wells","year":"2002","journal-title":"Endocr Rev"},{"key":"10.1016\/j.gofs.2021.03.015_bib1080","series-title":"The National Institutes of Health (NIH) consensus development program: osteoporosis prevention, diagnosis, and therapy","author":"Cranney","year":"2000"},{"key":"10.1016\/j.gofs.2021.03.015_bib1085","first-page":"330","article-title":"A randomized controlled trial of four doses of transdermal estradiol for preventing postmenopausal bone loss. Transdermal Estradiol Investigator Group","volume":"94","author":"Weiss","year":"1999","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.gofs.2021.03.015_bib1090","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S8756-3282(99)00076-9","article-title":"A dose-ranging trial of a matrix transdermal 17beta-estradiol for the prevention of bone loss in early postmenopausal women. International Study Group","volume":"24","author":"Delmas","year":"1999","journal-title":"Bone"},{"key":"10.1016\/j.gofs.2021.03.015_bib1095","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s001980070031","article-title":"Long-term continuous combined hormone replacement therapy in the prevention of postmenopausal bone loss: a comparison of high- and low-dose estrogen-progestin regimens","volume":"11","author":"Heikkinen","year":"2000","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.gofs.2021.03.015_bib1100","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/s00198-004-1773-4","article-title":"Bone response to treatment with lower doses of conjugated estrogens with and without medroxyprogesterone acetate in early postmenopausal women","volume":"16","author":"Lindsay","year":"2005","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.gofs.2021.03.015_bib1105","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1001\/jama.287.20.2668","article-title":"Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women","volume":"287","author":"Lindsay","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.gofs.2021.03.015_bib1110","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0378-5122(01)00257-2","article-title":"The effect of low-dose conjugated equine estrogens and cyclic MPA on bone density","volume":"41","author":"Gass","year":"2002","journal-title":"Maturitas"},{"key":"10.1016\/j.gofs.2021.03.015_bib1115","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1001\/archinte.1997.00440430091011","article-title":"Low-dose esterified estrogen therapy: effects on bone, plasma estradiol concentrations, endometrium, and lipid levels. Estratab\/Osteoporosis Study Group","volume":"157","author":"Genant","year":"1997","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.gofs.2021.03.015_bib1120","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/0140-6736(90)91801-G","article-title":"Effects of transdermal versus oral hormone replacement therapy on bone density in spine and proximal femur in postmenopausal women","volume":"336","author":"Stevenson","year":"1990","journal-title":"Lancet"},{"issue":"Suppl. 1","key":"10.1016\/j.gofs.2021.03.015_bib1125","first-page":"30","article-title":"Oral versus transdermal hormone replacement therapy","volume":"38","author":"Stevenson","year":"1993","journal-title":"Int J Fertil Menopausal Stud"},{"key":"10.1016\/j.gofs.2021.03.015_bib1130","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/BF01622195","article-title":"Long-term effects of transdermal and oral hormone replacement therapy on postmenopausal bone loss","volume":"4","author":"Hillard","year":"1994","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.gofs.2021.03.015_bib1135","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1001\/jama.1996.03540170033029","article-title":"Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen\/progestin interventions (PEPI) trial. The Writing Group for the PEPI","volume":"276","author":"The Writing Group for the PEPI","year":"1996","journal-title":"JAMA"},{"key":"10.1016\/j.gofs.2021.03.015_bib1140","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1359\/jbmr.1999.14.9.1583","article-title":"The relationship of biochemical markers of bone turnover to bone density changes in postmenopausal women: results from the Postmenopausal Estrogen\/Progestin Interventions (PEPI) trial","volume":"14","author":"Marcus","year":"1999","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.gofs.2021.03.015_bib1145","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1001\/archinte.160.20.3065","article-title":"How many women lose bone mineral density while taking hormone replacement therapy? Results from the Postmenopausal Estrogen\/Progestin Interventions Trial","volume":"160","author":"Greendale","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.gofs.2021.03.015_bib1150","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1067\/mob.2002.122852","article-title":"Norethisterone acetate in combination with estrogen: effects on the skeleton and other organs. A review","volume":"187","author":"Riis","year":"2002","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.gofs.2021.03.015_bib1155","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/0026-0495(90)90082-N","article-title":"Time-dependent variations in bone turnover parameters during 2 months\u2019 cyclic treatment with different doses of combined estrogen and progestogen in postmenopausal women","volume":"39","author":"Johansen","year":"1990","journal-title":"Metabolism"},{"key":"10.1016\/j.gofs.2021.03.015_bib1160","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0301-2115(01)00382-7","article-title":"Effect of continuous and sequential oral estrogen-progestogen replacement regimens on postmenopausal bone loss: a 2-year prospective study","volume":"99","author":"Figueras","year":"2001","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.gofs.2021.03.015_bib1165","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1001\/jama.2017.16952","article-title":"Hormone therapy for the primary prevention of chronic conditions in postmenopausal women: evidence report and systematic review for the US Preventive Services Task Force","volume":"318","author":"Gartlehner","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.gofs.2021.03.015_bib1170","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1001\/jama.291.18.2212","article-title":"Fracture incidence in relation to the pattern of use of hormone therapy in postmenopausal women","volume":"291","author":"Banks","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.gofs.2021.03.015_bib1175","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/jama.290.13.1729","article-title":"Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial","volume":"290","author":"Cauley","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.gofs.2021.03.015_bib1180","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/jbmr.3641","article-title":"Change in bone density and reduction in fracture risk: a meta-regression of published trials","volume":"34","author":"Bouxsein","year":"2019","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.gofs.2021.03.015_bib1185","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/GME.0000000000000519","article-title":"Effect of hormone therapy on the risk of bone fractures: a systematic review and meta-analysis of randomized controlled trials","volume":"23","author":"Zhu","year":"2016","journal-title":"Menopause"},{"key":"10.1016\/j.gofs.2021.03.015_bib1190","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/aje\/kwr044","article-title":"Risk of osteoporotic fractures after discontinuation of menopausal hormone therapy: results from the E3N cohort","volume":"174","author":"Engel","year":"2011","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.gofs.2021.03.015_bib1195","first-page":"243","article-title":"Effect of low-dose or standard-dose conjugated equine estrogen combined with different progesterone on bone density in menopause syndrome women","volume":"53","author":"Zuo","year":"2018","journal-title":"Zhonghua Fu Chan Ke Za Zhi"},{"key":"10.1016\/j.gofs.2021.03.015_bib1200","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/PL00004180","article-title":"A combination of low doses of 17 beta-estradiol and norethisterone acetate prevents bone loss and normalizes bone turnover in postmenopausal women","volume":"11","author":"Delmas","year":"2000","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.gofs.2021.03.015_bib1205","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1056\/NEJM198606193142505","article-title":"Biologic effects of transdermal estradiol","volume":"314","author":"Chetkowski","year":"1986","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gofs.2021.03.015_bib1210","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/0002-9378(82)90218-6","article-title":"Comparison of pharmacodynamic properties of various estrogen formulations","volume":"144","author":"Mashchak","year":"1982","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.gofs.2021.03.015_bib1215","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/0002-9378(92)91706-G","article-title":"Hormone treatment of endometriosis: the estrogen threshold hypothesis","volume":"166","author":"Barbieri","year":"1992","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.gofs.2021.03.015_bib1220","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0002-9343(96)00387-7","article-title":"Hormone replacement therapy in postmenopausal women: urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density","volume":"102","author":"Chesnut","year":"1997","journal-title":"Am J Med"},{"key":"10.1016\/j.gofs.2021.03.015_bib1225","first-page":"261","article-title":"Prevention of postmenopausal bone loss by long-term parenteral administration of 17beta-estradiol: comparison of percutaneous and transdermal route","author":"Ribot","year":"1990","journal-title":"Rev Fr Endocrinol Clin"},{"key":"10.1016\/j.gofs.2021.03.015_bib1230","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3109\/09513598909152465","article-title":"Preventive effects of transdermal administration of 17 beta-estradiol on postmenopausal bone loss: a 2-year prospective study","volume":"3","author":"Ribot","year":"1989","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.gofs.2021.03.015_bib1235","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0378-5122(01)00287-0","article-title":"Estrogen receptor alpha polymorphism as a genetic marker for bone loss, vertebral fractures and susceptibility to estrogen","volume":"41","author":"Kobayashi","year":"2002","journal-title":"Maturitas"},{"key":"10.1016\/j.gofs.2021.03.015_bib1240","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1046\/j.1365-2265.2000.00979.x","article-title":"Oestrogen-receptor-alpha gene polymorphism affects response in bone mineral density to oestrogen in post-menopausal women","volume":"52","author":"Ongphiphadhanakul","year":"2000","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.gofs.2021.03.015_bib1245","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1007\/s00198-008-0661-8","article-title":"Assessing response to osteoporosis therapy","volume":"19","author":"Lewiecki","year":"2008","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.gofs.2021.03.015_bib1250","doi-asserted-by":"crossref","first-page":"465","DOI":"10.7326\/M15-2937","article-title":"Change in bone mineral density is an indicator of treatment-related antifracture effect in routine clinical practice: a registry-based cohort study","volume":"165","author":"Leslie","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.gofs.2021.03.015_bib1255","series-title":"Markers of bone turnover and rates of bone loss during three years\u02bc combined hormone replacement therapy","author":"Nilas","year":"1996"},{"key":"10.1016\/j.gofs.2021.03.015_bib1260","first-page":"161","article-title":"Adequacy of hormone replacement therapy for osteoporosis prevention assessed by serum oestradiol measurement, and the degree of association with menopausal symptoms","volume":"47","author":"Rodgers","year":"1997","journal-title":"Br J Gen Pract"},{"key":"10.1016\/j.gofs.2021.03.015_bib1265","first-page":"18S","article-title":"Pharmacokinetic and pharmacologic variation between different estrogen products","volume":"35","author":"O\u2019Connell","year":"1995","journal-title":"J Clin Pharmacol"},{"issue":"Suppl. 1","key":"10.1016\/j.gofs.2021.03.015_bib1270","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/13697130500148875","article-title":"Pharmacology of estrogens and progestogens: influence of different routes of administration","volume":"8","author":"Kuhl","year":"2005","journal-title":"Climacteric"},{"key":"10.1016\/j.gofs.2021.03.015_bib1275","first-page":"758","article-title":"Pharmacokinetics of percutaneous estradiol: a crossover study using a gel and a transdermal system in comparison with oral micronized estradiol","volume":"77","author":"Scott","year":"1991","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.gofs.2021.03.015_bib1280","series-title":"Osteoporosis","article-title":"Use of plasma 17beta-estradiol as a guideline for parenteral administration of estrogen for the prevention and treatment of osteoporosis","author":"Wimalawansa","year":"1990"},{"key":"10.1016\/j.gofs.2021.03.015_bib1285","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1007\/BF00316876","article-title":"Minimal levels of serum estradiol prevent postmenopausal bone loss","volume":"51","author":"Reginster","year":"1992","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.gofs.2021.03.015_bib1290","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1210\/jcem.87.4.8415","article-title":"Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents","volume":"87","author":"Hochberg","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.gofs.2021.03.015_bib1295","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/jbmr.3355","article-title":"Treatment-related changes in bone turnover and fracture risk reduction in clinical trials of anti-resorptive drugs: a meta-regression","volume":"33","author":"Bauer","year":"2018","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.gofs.2021.03.015_bib1300","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s00198-017-3906-6","article-title":"International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates","volume":"28","author":"Diez-Perez","year":"2017","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.gofs.2021.03.015_bib1305","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1210\/jc.2004-0124","article-title":"Official positions of the international society for clinical densitometry","volume":"89","author":"Lewiecki","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.gofs.2021.03.015_bib1310","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1359\/jbmr.1999.14.8.1449","article-title":"Individual smallest detectable difference in bone mineral density measurements","volume":"14","author":"Ravaud","year":"1999","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.gofs.2021.03.015_bib1315","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jocd.2019.07.010","article-title":"Repeating measurement of bone mineral density when monitoring with dual-energy X-ray absorptiometry: 2019 ISCD Official Position","volume":"22","author":"Kendler","year":"2019","journal-title":"J Clin Densitom"},{"key":"10.1016\/j.gofs.2021.03.015_bib1320","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0140-6736(19)31709-X","article-title":"Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence","volume":"394","author":"Collaborative Group on Hormonal Factors in Breast Cancer","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.gofs.2021.03.015_bib1325","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1210\/jc.2019-00192","article-title":"Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: a network meta-analysis","volume":"104","author":"Barrionuevo","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.gofs.2021.03.015_bib1330","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/S0755-4982(06)74851-5","article-title":"Place du traitement hormonal substitutif dans la strat\u00e9gie de traitement de l\u2019ost\u00e9oporose post-m\u00e9nopausique et la pr\u00e9vention du risque fracturaire","volume":"35","author":"Ribot","year":"2006","journal-title":"Presse Med"},{"key":"10.1016\/j.gofs.2021.03.015_bib1335","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1007\/s00198-020-05497-8","article-title":"Is there a role for menopausal hormone therapy in the management of postmenopausal osteoporosis?","volume":"31","author":"Rozenberg","year":"2020","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.gofs.2021.03.015_bib1340","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.bone.2003.12.021","article-title":"Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study","volume":"34","author":"Bagger","year":"2004","journal-title":"Bone"},{"key":"10.1016\/j.gofs.2021.03.015_bib1345","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1097\/01.GME.0000123641.76105.B5","article-title":"Changes in bone density and turnover after alendronate or estrogen withdrawal","volume":"11","author":"Wasnich","year":"2004","journal-title":"Menopause"},{"key":"10.1016\/j.gofs.2021.03.015_bib1350","doi-asserted-by":"crossref","first-page":"875","DOI":"10.7326\/0003-4819-137-11-200212030-00008","article-title":"Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial","volume":"137","author":"Greenspan","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.gofs.2021.03.015_bib1355","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1001\/archinte.162.6.665","article-title":"Bone mass response to discontinuation of long-term hormone replacement therapy: results from the Postmenopausal Estrogen\/Progestin Interventions (PEPI) Safety Follow-up Study","volume":"162","author":"Greendale","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.gofs.2021.03.015_bib1360","doi-asserted-by":"crossref","first-page":"4914","DOI":"10.1210\/jc.2002-020727","article-title":"Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers","volume":"87","author":"Gallagher","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.gofs.2021.03.015_bib1365","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s001980170107","article-title":"Withdrawal of hormone replacement therapy is associated with significant vertebral bone loss in postmenopausal women","volume":"12","author":"Tr\u00e9mollieres","year":"2001","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.gofs.2021.03.015_bib1370","doi-asserted-by":"crossref","first-page":"5700","DOI":"10.1210\/jcem.86.12.8079","article-title":"Timing of estrogen replacement therapy for optimal osteoporosis prevention","volume":"86","author":"Cauley","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.gofs.2021.03.015_bib1375","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1001\/jama.1997.03540310041032","article-title":"Timing of postmenopausal estrogen for optimal bone mineral density. The Rancho Bernardo Study","volume":"277","author":"Schneider","year":"1997","journal-title":"JAMA"},{"key":"10.1016\/j.gofs.2021.03.015_bib1380","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1080\/13697130701370435","article-title":"The effects of short-term hormone replacement therapy on long-term bone mineral density","volume":"10","author":"Middleton","year":"2007","journal-title":"Climacteric"},{"key":"10.1016\/j.gofs.2021.03.015_bib1385","doi-asserted-by":"crossref","first-page":"5004","DOI":"10.1210\/jc.2016-2695","article-title":"The benefit of menopausal hormone therapy on bone density and microarchitecture persists after its withdrawal","volume":"101","author":"Papadakis","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.gofs.2021.03.015_bib1390","first-page":"302","article-title":"No increase in fractures after stopping hormone therapy: results from the Women's Health Initiative","volume":"102","author":"Watts","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.gofs.2021.03.015_bib1395","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1001\/jama.291.18.2212","article-title":"Fracture incidence in relation to the pattern of use of hormone therapy in postmenopausal women","volume":"291","author":"Banks","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.gofs.2021.03.015_bib1400","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/01.AOG.0000114986.14806.37","article-title":"Rapid loss of hip fracture protection after estrogen cessation: evidence from the National Osteoporosis Risk Assessment","volume":"103","author":"Yates","year":"2004","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.gofs.2021.03.015_bib1405","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/01.GME.0000086467.82759.DA","article-title":"Recency and duration of postmenopausal hormone therapy: effects on bone mineral density and fracture risk in the National Osteoporosis Risk Assessment (NORA) study","volume":"10","author":"Barrett-Connor","year":"2003","journal-title":"Menopause"},{"key":"10.1016\/j.gofs.2021.03.015_bib1410","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1097\/gme.0b013e31821b01c7","article-title":"Hip fracture in postmenopausal women after cessation of hormone therapy: results from a prospective study in a large health management organization","volume":"18","author":"Karim","year":"2011","journal-title":"Menopause"},{"key":"10.1016\/j.gofs.2021.03.015_bib1415","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archinte.163.7.789","article-title":"Alendronate prevents loss of bone density associated with discontinuation of hormone replacement therapy: a randomized controlled trial","volume":"163","author":"Ascott-Evans","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.gofs.2021.03.015_bib1420","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1097\/01.gme.0000184425.73567.12","article-title":"Oral hormone therapy with 17beta-estradiol and 17beta-estradiol in combination with norethindrone acetate in the prevention of bone loss in early postmenopausal women: dose-dependent effects","volume":"12","author":"Greenwald","year":"2005","journal-title":"Menopause"},{"key":"10.1016\/j.gofs.2021.03.015_bib1425","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/BF01774018","article-title":"Biochemical markers of bone turnover to monitor the bone response to postmenopausal hormone replacement therapy","volume":"5","author":"Riis","year":"1995","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.gofs.2021.03.015_bib1430","first-page":"1904","article-title":"The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation","volume":"82","author":"Rosen","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.gofs.2021.03.015_bib1435","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s00774-003-0460-4","article-title":"Significance of serum CrossLaps as a predictor of changes in bone mineral density during estrogen replacement therapy; comparison with serum carboxyterminal telopeptide of type I collagen and urinary deoxypyridinoline","volume":"22","author":"Okabe","year":"2004","journal-title":"J Bone Miner Metab"},{"key":"10.1016\/j.gofs.2021.03.015_bib0720","first-page":"546","article-title":"Prevention of femoral and lumbar bone loss with hormone replacement therapy and vitamin D3 in early postmenopausal women: a population-based 5-year randomized trial","volume":"84","author":"Komulainen","year":"1999","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Gyn\u00e9cologie Obst\u00e9trique Fertilit\u00e9 & S\u00e9nologie\u00a0"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468718921000647?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468718921000647?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T09:42:13Z","timestamp":1762854133000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468718921000647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":144,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S2468718921000647"],"URL":"https:\/\/doi.org\/10.1016\/j.gofs.2021.03.015","relation":{},"ISSN":["2468-7189"],"issn-type":[{"value":"2468-7189","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"M\u00e9nopause, traitement hormonal de m\u00e9nopause et ost\u00e9oporose. RPC Les femmes m\u00e9nopaus\u00e9es du CNGOF et du GEMVi","name":"articletitle","label":"Article Title"},{"value":"Gyn\u00e9cologie Obst\u00e9trique Fertilit\u00e9 & S\u00e9nologie\u00a0","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gofs.2021.03.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}